Efficacy and Safety of Litifilimab for Cutaneous Lupus Erythematosus
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
N. Engl. J. Med 2022 Jul 28;387(4)321-331, VP Werth, RA Furie, J Romero-Diaz, S Navarra, K Kalunian, RF van Vollenhoven, F Nyberg, BH Kaffenberger, SZ Sheikh, G Radunovic, X Huang, G Clark, H Carroll, H Naik, F Gaudreault, A Meyers, C Barbey, C Musselli, N FranchimontFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.